...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Biomolecular Structure and Dynamics >Remdesivir in the treatment of coronavirus disease 2019 (COVID-19): a simplified summary
【24h】

Remdesivir in the treatment of coronavirus disease 2019 (COVID-19): a simplified summary

机译：RemdesiviR治疗冠状病毒疾病2019（Covid-19）：简化摘要

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The pandemic of COVID-19 (Coronavirus Disease-2019) is an extremely contagious respiratory illness due to a novel coronavirus, SARS-CoV-2. Certain drugs have several protein targets and many illnesses share overlapping molecular paths. In such cases, reusing drugs for more than one objective and finding their novice uses can considerably decrease the time in finding new cures for unforeseen diseases. Remdesivir has been recently a strong candidate for the treatment of Covid-19. In this commentary, we have portrayed the structure of the coronavirus in a simple way as well as the site where remdesivir acts. We have also displayed the ongoing clinical trials, as well as a published study that was conducted on compassionate base. The covid-19 pandemic might wean down by the end of summer 2020, but the risk of seasonality exists. Therefore, future disposal of agents such as remdesivir might be crucial for ensuring an efficient treatment, decrease mortality and allow early discharge. Communicated by Ramaswamy H. Sarma
机译：C2019冠状病毒疾病流行是新型冠状病毒SARS COV-2引起的一种传染性疾病。某些药物有几个蛋白质靶点，许多疾病有重叠的分子途径。在这种情况下，为不止一个目标重复使用药物，并找到它们的新手用途，可以大大缩短为不可预见的疾病寻找新疗法的时间。Re2019冠状病毒疾病是治疗COVID-19的一个强有力的候选药物。在这篇评论中，我们用一种简单的方式描述了冠状病毒的结构，以及雷姆德西韦的作用部位。我们还展示了正在进行的临床试验，以及在富有同情心的基础上进行的一项已发表的研究。CVID2019冠状病毒疾病可能在2020年底结束，但季节性风险存在。因此，未来处置雷姆德西韦等药物可能对确保有效治疗、降低死亡率和允许早期出院至关重要。由Ramaswamy H.Sarma传达

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号